Antibody Drug Conjugates: Re-emergence of an old modality for targeted therapies 

Learn more about the development of antibody drug conjugates – long used in the treatment of cancerous tumors – and their remarkable projected CAGR over the next few years. Explore considerations for their development, common challenges in discovery and manufacturing, and proven strategies for moving ahead, with insights from Pharma Ignite and Syngene.

Read the White paper now for more information about:

• Understanding the current landscape and future opportunities for the ADC space
• Overcoming challenges in ADC discovery, including payload selection, linker design, and purification
• Supporting discovery, development, and manufacturing with solutions from global CRO/CDMO Syngene
• Leveraging Syngene’s proven track record and extensive experience across a full array of ADC services